In 2023, the value of antiarrhythmic medicine sales in Italy stood at a constant level of 1.5 US Dollars per capita. From 2024 to 2028, there is no anticipated year-on-year change, with sales forecasted to remain stable at 1.5 US Dollars per capita annually, indicating a zero growth rate and a Compound Annual Growth Rate (CAGR) of 0% over the five-year period. This suggests a stagnant market without growth in sales volume or value.
Future trends to watch for include potential market shifts driven by demographic changes, healthcare policy reforms, advancements in treatment technologies, and the introduction of new and improved antiarrhythmic drugs. Additionally, increasing awareness of heart health and preventive care may influence market dynamics.
